

THE PROPOSAL BY THE NOMINATION COMMITTEE OF Q-LINEA AB (PUBL) FOR ELECTION OF MEMBERS OF THE BOARD OF DIRECTORS

The nomination committee of Q-linea AB (publ) submits the following proposals to be presented at the annual general meeting of shareholders to be held on 25 May 2021, with regard to the number and election of members of the board of directors.

The nomination committee proposes seven members of the board of directors and no deputy directors.

The nomination committee proposes re-election of all board members, i.e. Erika Kjellberg Eriksson, Marianne Hansson, Hans Johansson, Mats Nilsson, Marcus Storch, Per-Olof Wallström and Mario Gualano, each for a term of office until the end of the next annual general meeting. Furthermore, the nomination committee proposes Erika Kjellberg Eriksson to be re-elected as chairperson of the board of directors.

Information about all persons proposed as members of the board of directors of Q-linea, the nomination committee's statement regarding the proposal for the board of directors and the nomination committee's complete proposal will be available on Q-linea's website, www.qlinea.com in connection with the issuance of the notice to attend the annual general meeting 2021.

The nomination committee has been appointed according to the principles adopted by the annual general meeting 2020 and consists of Öystein Engebretsen (Investment AB Öresund, chairperson of the nomination committee), Erika Kjellberg Eriksson (Nexttobe AB, chairperson of the board) and Ulrik Grönvall (Swedbank Robur Fonder).

Uppsala in April 2021
The nomination committee of Q-linea AB (publ)

For more information, please contact:

Jonas Jarvius, CEO, Q-linea AB
Jonas.Jarvius@qlinea.com
+46 (0) 70-323 77 60

Anders Lundin, CFO, Q-linea AB
Anders.Lundin@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

Attachments

[The proposal by the nomination committee of Q-linea AB \(publ\) for election of members of the board of directors](#)